Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia

Translational Psychiatry

Volumn 6, Issue , 2016, Pages

  Giovanoli, S ^a   Engler, H ^b   Engler, A ^b   Richetto, J ^c,d   Feldon, J ^a   Riva, M A ^c   Schedlowski, M ^b   Meyer, U ^a,d  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DIZOCILPINE; INTERLEUKIN 1BETA; MINOCYCLINE; POLYINOSINIC POLYCYTIDYLIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT; CENTRAL STIMULANT AGENT; DIZOCILPINE MALEATE; IL1B PROTEIN, MOUSE; INTERFERON INDUCING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG EFFECT; EARLY LIFE STRESS; FEMALE; HIPPOCAMPUS; MALE; MICROGLIA; MOUSE; NERVE CELL DIFFERENTIATION; NEWBORN; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PROTEIN EXPRESSION; SCHIZOPHRENIA; ANIMAL; DISEASE MODEL; DRUG EFFECTS; MENTAL STRESS; METABOLISM; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; PSYCHOLOGY; PSYCHOSIS;

AMPHETAMINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HIPPOCAMPUS; INTERFERON INDUCERS; INTERLEUKIN-1BETA; MICE; MICROGLIA; MINOCYCLINE; POLY I-C; PREFRONTAL CORTEX; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; PREPULSE INHIBITION; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL;

EID: 84963705460     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.38     Document Type: Article

References (48)

1. Deverman BE, Patterson PH. Cytokines and CNS development. Neuron 2009; 64: 61-78.)
2. McAllister AK. Major histocompatibility complex I in brain development and schizophrenia. Biol Psychiatry 2014; 75: 262-268.)
3. Meyer U, Yee BK, Feldon J. The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist 2007; 13: 241-256.)
4. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167: 261-280.)
5. Parboosing R, Bao Y, Shen L, Schaefer CA, Brown AS. Gestational influenza and bipolar disorder in adult offspring. JAMA Psychiatry 2013; 707: 677-685.)
6. Atladottir HO, Henriksen TB, Schendel DE, Parner ET. Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study. Pediatrics 2012; 130: e1447-e1454.)
7. Johnson J, Anderson B, Pass RF. Prevention of maternal and congenital cytomegalovirus infection. Clin Obstet Gynecol 2012; 55: 521-530.)
8. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42: 1-8.)
9. Harvey L, Boksa P. Prenatal and postnatal animal models of immune activation: relevance to a range of neurodevelopmental disorders. Dev Neurobiol 2012; 72: 1335-1348.)
10. Meyer U. Prenatal poly(I:C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry 2014; 75: 307-315.)
11. Larsson S, Aas M, Klungsyr O, Agartz I, Mork E, Steen NE et al. Patterns of childhood adverse events are associated with clinical characteristics of bipolar disorder. BMC Psychiatry 2013; 13: 97.)
12. Varese F, Smeets F, Drukker M, Lieverse R, Lataster T, Viechtbauer W et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patientcontrol, prospective- and cross-sectional cohort studies. Schizophr Bull 2012; 38: 661-671.)
13. Giovanoli S, Engler H, Engler A, Richetto J, Voget M, Willi R et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 2013; 339: 1095-1099.)
14. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009; 46: 94-102.)
15. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ et al. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006; 26: 1157-1164.)
16. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 2008; 5: 15.)
17. Hinwood M, Tynan RJ, Charnley JL, Beynon SB, Day TA, Walker FR. Chronic stress induced remodeling of the prefrontal cortex: structural re-organization of microglia and the inhibitory effect of minocycline. Cereb Cortex 2013; 23: 1784-1797.)
18. Siller SS, Broadie K. Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. Neural Plast 2012; 2012: 124548.)
19. Mattei D, Djodari-Irani A, Hadar R, Pelz A, de Cossio LF, Goetz T et al. Minocycline rescues decrease in neurogenesis, increase in microglia cytokines and deficits in sensorimotor gating in an animal model of schizophrenia. Brain BehavImmun 2014; 38: 175-184.)
20. Zhu F, Liu Y, Zheng Y, Zhao J. Minocycline alleviates behavioral deficits and inhibits microglial activation induced by intrahippocampal administration of Granulocyte-Macrophage Colony -Stimulating Factor in adult rats. Neuroscience 2014; 266: 275-281.)
21. Zhu F, Zheng Y, Ding YQ, Liu Y, Zhang X, Wu R et al. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PLoS One 2014; 9: e93966.)
22. Zhu F, Zheng Y, Liu Y, Zhang X, Zhao J. Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic-polyribocytidilic acid. Psychiatry Res 2014; 219: 680-686.)
23. Meyer U, Feldon J, Fatemi SH. In vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobehav Rev 2009; 33: 1061-1079.)
24. Giedd JN. Structural magnetic resonance imaging of the adolescent brain. Ann NY Acad Sci 2004; 1021: 77-85.)
25. Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaituzis AC et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc. Proc Natl Acad Sci USA 2004; 101: 8174-8179.)
26. Paus T, Keshavan M, Giedd JN. Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008; 9: 947-957.)
27. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-145.)
28. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 2007; 1154: 154-162.)
29. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007; 32: 2004-2010.)
30. Borrell J, Vela JM, Arevalo-Martin A, Molina-Holgado E, Guaza C. Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology 2002; 26: 204-205.)
31. Manitz MP, Esslinger M, Wachholz S, Plumper J, Friebe A, Juckel G et al. The role of microglia during life span in neuropsychiatric disease-an animal study. Schizophr Res 2013; 143: 221-222.)
32. Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A et al. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 2014; 129: 163-179.)
33. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-1193.)
34. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Res 2014; 215: 540-546.)
35. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149.)
36. Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TG et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry 2015; 77: 147-157.)
37. Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G et al. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18 F]-FEPPA. Schizophr Bull 2015; 41: 85-93.)
38. Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014; 71: 1121-1128.)
39. Pasternak O, Westin CF, Dahlben B, Bouix S, Kubicki M. The extent of diffusion MRI markers of neuroinflammation and white matter deterioration in chronic schizophrenia. Schizophr Res 2015; 161: 113-118.)
40. Russell A, Ciufolini S, Gardner-Sood P, Bonaccorso S, Gaughran F, Dazzan P et al. Inflammation and metabolic changes in First Episode Psychosis: preliminary results from a longitudinal study. Brain Behav Immun 2015; 49: 25-29.)
41. Eiland L, Romeo RD. Stress and the developing adolescent brain. Neuroscience 2013; 249: 162-171.)
42. Schneider M. Adolescence as a vulnerable period to alter rodent behavior. Cell Tissue Res 2013; 354: 99-106.)
43. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;42: 20-34.)
44. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci 2009; 3: 14.)
45. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.)
46. Bilimoria PM, Stevens B. Microglia function during brain development: new insights from animal models. Brain Res 2015; 1617: 7-17.)
47. Schafer DP, Lehrman EK, Stevens B. The quad-partite synapse: microglia-synapse interactions in the developing and mature CNS. Glia 2013; 61: 24-36.)
48. Orsucci D, Calsolaro V, Mancuso M, Siciliano G. Neuroprotective effects of tetracyclines: molecular targets, animal models and human disease. CNS Neurol Disord Drug Targets 2009; 8: 222-231.